Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Biochem Biophys Res Commun 2017;490:247-52.ArticlePubMed 82
"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." December 11, 2025
Semaglutide demonstrates consistent weight reduction outcomes, which has driven high physician confidence and patient acceptance
In a randomized controlled study, exenatide administered once a week for 18 months did not change carotid plaque volume or composition [173]
GLP-1 RAs significantly increased the likelihood of achieving 5% and 10% weight loss compared to placebo, with relative risks (RR) of 2.51 and 4.11, respectively
US$ 20.82
US$ 29.20
US$ 28.36
US$ 23.26
US$ 23.28
